Every piece MicroCap Desk has published on Precision BioSciences, newest first. Independent editorial — we take no compensation from the companies we cover.
Precision's ELIMINATE-B biopsy data show its editor cutting hepatitis B cccDNA, with HBsAg declines in all patients.
In vivo gene editing as the next frontier after CRISPR-Cas9.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.